{
  "title": "Paper_1094",
  "abstract": "pmc Brief Bioinform Brief Bioinform 721 bib bib Briefings in Bioinformatics 1467-5463 1477-4054 Oxford University Press PMC12477610 PMC12477610.1 12477610 12477610 41020523 10.1093/bib/bbaf510 bbaf510 1 Problem Solving Protocol AcademicSubjects/SCI01060 AdaSemb: an adaptive knowledge-driven deep learning framework integrating cancer protein assemblies for predicting PI3Kα inhibitor response and resistance https://orcid.org/0009-0003-4559-1385 Li Zaiduo  Key Laboratory of Information Fusion Estimation and Detection, Heilongjiang University Xuefu Road, Harbin 150080 China https://orcid.org/0000-0002-6524-9443 Yang Qiang  School of Computer Science and Technology, Harbin Institute of Technology West Dazhi Street, Harbin 150001 China https://orcid.org/0000-0003-4952-9178 Xu Long  School of Computer Science and Technology, Harbin Institute of Technology West Dazhi Street, Harbin 150001 China https://orcid.org/0000-0001-8022-9793 Dong Weihe  School of Computer Science and Technology, Harbin Institute of Technology West Dazhi Street, Harbin 150001 China https://orcid.org/0009-0009-2567-1488 Yang Xiaochuan  Key Laboratory of Information Fusion Estimation and Detection, Heilongjiang University Xuefu Road, Harbin 150080 China https://orcid.org/0000-0002-9738-2361 Zhang Xianyu  Department of Breast Surgery, Harbin Medical University Cancer Hospital Haping Road, Harbin 150081 China https://orcid.org/0000-0002-4008-702X Yang Tiansong  The First Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine, and Traditional Chinese Medicine Informatics Key Laboratory of Heilongjiang Province Heping Road, 150040, Harbin China https://orcid.org/0000-0002-6645-6890 Li Xiaokun  School of Computer Science and Technology, Harbin Institute of Technology West Dazhi Street, Harbin 150001 China  School of Computer Science and Technology, Heilogjiang University Xuefu Road, Harbin 150080 China  Postdoctoral Program of Heilongjiang Hengxun Technology Co., Ltd. Xuefu Road, Harbin 150090 China  Shandong Hengxun Technology Co., Ltd. Miaoling Road, Qingdao 266100 China https://orcid.org/0000-0003-1124-3561 Liu Mingliang  Key Laboratory of Information Fusion Estimation and Detection, Heilongjiang University Xuefu Road, Harbin 150080 China Corresponding authors. Xiaokun Li, School of Computer Science and Technology, Harbin Institute of Technology, West Dazhi Street, Harbin 150001, China. E-mail: 24b303024@stu.hit.edu.cn 2002039@hlju.edu.cn 9 2025 29 9 2025 26 5 495954 bbaf510 23 4 2025 03 8 2025 07 9 2025 29 09 2025 30 09 2025 30 09 2025 © The Author(s) 2025. Published by Oxford University Press. 2025 https://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License ( https://creativecommons.org/licenses/by-nc/4.0/ Abstract Protein kinases regulate diverse cellular functions, including cell cycle progression, metabolism, differentiation, and survival, with their dysregulation implicated in multiple carcinogenic processes. Phosphatidylinositol 3-kinase alpha inhibitors (PI3K \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$ \\alpha $\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$ \\alpha $\\end{document} PI3Kα inhibitor cancer protein systems map drug resistance drug response prediction Natural Science Foundation of Heilongjiang Province of China LH2020F046 Double First Class Discipline Collaborative Innovation foundation of Heilongjiang province of China LJGXCG2023-54 pmc-status-qastatus 0 pmc-status-live yes pmc-status-embargo no pmc-status-released yes pmc-prop-open-access yes pmc-prop-olf no pmc-prop-manuscript no pmc-prop-legally-suppressed no pmc-prop-has-pdf yes pmc-prop-has-supplement yes pmc-prop-pdf-only no pmc-prop-suppress-copyright no pmc-prop-is-real-version no pmc-prop-is-scanned-article no pmc-prop-preprint no pmc-prop-in-epmc yes Introduction Health informatics plays a crucial role in drug development, diagnosis, regulatory elements, and protein/enzyme targeting [ 1–3 4–7 Aberrant activation of the phosphatidylinositol 3-kinase (PI3K) signaling pathway is a key molecular hallmark of various malignancies, with particular prominence in breast cancer [ 8 \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$ \\alpha $\\end{document} 9–11 12 13 \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$ \\alpha $\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$ \\alpha $\\end{document} 14 15 16 Existing research on alpelisib resistance has primarily identified several single-molecule biomarkers, including PIK3CA secondary mutations (e.g. H1047R mutation), PTEN loss, and AKT1 activation mutations. These can reactivate the PI3K signaling pathway, leading to the gradual loss of treatment efficacy [ 17–19 15 20 16 Current research has predominantly focused on single-molecule biomarkers, while progress in studies at the assembly level remains limited. However, biomarkers at the assembly level may play a crucial role in elucidating resistance mechanisms and their interactions. Therefore, it is important to explore the multimolecular mechanisms underlying PI3K \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$ \\alpha $\\end{document} 17 21 With the advancement of precision medicine, deep learning-based drug drug response prediction (DRP) models have gained significant attention in cancer [ 22 23 24 25 26 27 28 29 30 To address these limitations, novel Visible Neural Network (VNN) architectures have emerged. These architectures incorporate cellular components and functional knowledge graphs, enabling the prediction of biomedical outcomes from sparse genetic feature sets. Moreover, their predictions can be mapped to changes in molecular mechanisms and pathway states, facilitating model interpretability [ 29 31–33 et al 32 34 35 et al 36 Fig. 1a 36 Figure 1 Rationale and framework for the AdaSemb. (a) Diagram depicting the construction process of the NeST protein assembly hierarchy in cancer. (b) Workflow of AdaSemb for predicting drug resistance. (c) AdaSemb deep neural network architecture. (d) Structure of CDAN, used to transfer knowledge from the chemical structure domain to the drug response domain. (e) Heatmap of gene alterations across 718 genes and 1244 CCLs, with different colors representing varying gene alteration statuses. Created by BioRender.com. In this study, we developed a visualizable deep learning framework based on the NeST map, incorporating an adaptive domain knowledge learning mechanism. This model not only explores how genetic variation patterns regulate tumor responses to PI3K \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$ \\alpha $\\end{document} Fig. 1c Results Development of AdaSemb To predict PI3K \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$ \\alpha $\\end{document} 37 38 39 Fig. 1e 31 Fig. 1b c Fig. 1c Fig. S2a 40 Supplementary Materials Supplementary Table 1 \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$ \\alpha $\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$n=35$\\end{document} In the second stage, we incorporated a conditional domain adversarial network (CDAN) into the AdaSemb-DRP framework to adjust representations and enhance cross-domain generalization of predictive performance ( Fig. 1d \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$ \\alpha $\\end{document} Fig. 1c To improve clarity on the data flow and component interdependencies in AdaSemb, we included a schematic diagram in Fig. S1 Supplementary Algorithm 1 We trained the AdaSemb model using drug response data from 1244 CCLs with genomic profiling [ 41 42 43 44 45 \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$\\alpha $\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$\\alpha $\\end{document} Model training and performance analysis We implemented a standard backpropagation-based neural network learning procedure (Methods) to construct AdaSemb drug response models for alpelisib and 34 benchmark drugs. Each model was trained to predict the area under the dose–response curve (AUDRC) based on the genomic alteration profiles of cell lines. Our dataset integrated genomic profiles from 718 clinically relevant genes across 1244 CCLs, sourced from comprehensive panels (e.g. FoundationOne CDx, Tempus xT). While this provided a broad representation, missing values in mutation or copy number variation data were imputed. We used a k-nearest neighbors approach for imputation. This reduced sparsity-related bias and ensured stable training. We employed nested five-fold cross validation (Methods) for training and performance evaluation. In each validation round, the dataset was randomly partitioned into a training set, validation set, and test set at a 3:1:1 ratio. The validation set was employed for model assessment and hyperparameter optimization. The test set consisted of held-out cell lines unseen during training or validation. Although nested cross-validation is computationally demanding, it efficiently separates model testing from hyperparameter tuning. It also maximizes the number of samples available for testing. To address overfitting, we implemented early stopping based on validation loss, L2 regularization, and nested cross-validation. These measures accountted for AdaSemb’s hierarchical architecture and domain adaptation module. They resulted in performance drops of <5% between training and test sets. We compared the AdaSemb method with eight state-of-the-art (SOTA) models, including four pathway-based models that incorporate gene-pathway memberships into their architectures: PathDSP [ 24 25 27 28 Fig. 2a Fig. S2b Fig. S2c Supplementary Table 2 Figure 2 Predictive performance of the alpelisib model. (a) Dot plot of model performance for each of 35 drugs for AdaSemb versus six alternate models; alpelisib model highlighted in pink. (b) ROC curves for predicting resistance or sensitivity to alpelisib; the marked points indicate cutoffs used to label samples as “resistant” or “sensitive” at different stringencies. (c) Survival curve analysis predicting sensitive or resistant status of PDX samples. (d) Kaplan–Meier survival curves (KM curves) of PFS for patients with BRCA, stratified by the AdaSemb prediction status. (e) Interaction network of proteins in NeST:138; the edges denote Integrated Association Stringency (IAS) scores used to assemble the NeST map [ 36 \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$ \\alpha $\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$ \\alpha $\\end{document} * P To classify continuous AUDRC predictions into discrete tumor response categories, we applied a threshold-based classification approach. Specifically, cell lines with AUDRC values below the lower threshold \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n${h_{{low}}}$\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n${h_{{high}}}$\\end{document} Fig. S3a \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n${h_{{low}}}$\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n${h_{{high}}}$\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$\\pm $\\end{document} Fig. S3b Supplementary Table 3 To mitigate class imbalance in sensitivity/resistance classification, we employed stratified sampling in nested five-fold cross validation and incorporated B.Acc as a primary metric alongside area under the receiver operating characteristic curve (ROC-AUC) and the area under the precision-recall curve (AUPR), demonstrating resilience against skewed distributions. Stricter thresholds enhanced classification precision and specificity but reduced sample coverage, as \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$\\sim $\\end{document} Fig. 2b Fig. S4a b Fig. S4c and d Cross-domain generalization evaluation and model adaptability analysis To comprehensively evaluate the generalization capability of AdaSemb on novel cell lines and drug data, and to validate the effectiveness of its domain adaptation module in cross-domain prediction tasks, we designed a challenging experiment using the GDSC dataset. We randomly divided experimental entities (cell lines, drugs, and their combinations) into five equal subsets. In each experimental round, one subset was held out as simulated novel entities, while the remaining four subsets, along with their corresponding drug response data, were used to train the predictive model, which was then tested on the new entities. We compared AdaSemb-PA and AdaSemb-DRP with various baseline models capable of generalization, as discussed in Section 2, across three generalization settings: cell line generalization, drug generalization, and joint cell line-drug generalization. In the cell line generalization task, AdaSemb-PA achieved the best results in both AUC ( Fig. 3a Fig. 3b Figure 3 Performance Comparison in Inductive Setting. (a) AUC scores for AdaSemb, along with the SOTA methods, in the inductive capability study. (b) AUPR scores for AdaSemb, along with the SOTA methods, in the inductive capability study. In the drug generalization task, all models exhibited performance degradation, due to the greater structural diversity of drugs compared with the more homogeneous genetic backgrounds of cell lines. However, AdaSemb-PA and AdaSemb-DRP still achieved the best results, with AdaSemb-DRP showing a significant improvement in cross-domain drug prediction by incorporating a domain adaptation module. Specifically, AdaSemb-DRP yielded an AUC of 0.6975 and AUPR of 0.4975, outperforming PathDSP (AUC: 0.6724, AUPR: 0.4711), XGBoost (AUC: 0.6933, AUPR: 0.4533), and five-layer MLP (AUC: 0.6359, AUPR: 0.4159), highlighting its robustness. In the joint cell line-drug generalization task, baseline models showed a substantial performance decline, particularly in AUPR ( Fig. 3b Fig. 3a Establishment of patient-derived xenografts and patient cohort characterization Next, the performance of AdaSemb was evaluated in a patient-derived xenograft (PDX) study [ 46 \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$n = 212$\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n${h_{{low}}}$\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n${h_{{high}}}$\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$ \\pm $\\end{document} Fig. 2 Supplementary Table 4 Following the xenograft analysis, we evaluated the performance of AdaSemb in predicting treatment outcomes using two independent clinical cohorts: 116 breast cancer patients from TCGA dataset and 63 HR+/HER2- breast cancer patients from cBioPortal [ 47 \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$ \\alpha $\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n${h_{{low}}}$\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n${h_{{high}}}$\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$ \\alpha $\\end{document} Fig. 2 Fig. S5 48 Molecular assemblies play a critical role in PI3K \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$ \\boldsymbol\\alpha $\\end{document} Given that AdaSemb successfully predicted drug responses in CCLs, PDX samples, and patients, we aimed to identify the key PA driving this process. Following previously established methods [ 31 Fig. S3c Supplementary Table 5 \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$ \\alpha $\\end{document} Fig. S3c Supplementary Table 5 Fig. 2e Fig. S3c \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$ \\alpha $\\end{document} Fig. 2f \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$ \\alpha $\\end{document} 12 49 Fig. 2g 50 Fig. 2g Fig. 2g In cell lines, AdaSemb identified 25 PA that were highly associated with alpelisib response prediction (importance score \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$ \\geq $\\end{document} Fig. S3c Lymphoid JAK-STAT assembly as a predictive biomarker for PI3K \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$ \\boldsymbol\\alpha $\\end{document} The Lymphoid JAK-STAT assembly (NeST:84) effectively integrates multiple rare mutations within PA to enhance prediction accuracy. This assembly comprises upstream cytokine receptors (CSF3R, EPOR, IFNAR2, IL6R) and downstream signaling molecules and effectors (JAK1/2/3, STAT3/6/5A/5B) that form a highly interactive signaling network ( Fig. 4c \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$ \\alpha $\\end{document} Fig. 4a Fig. 4b Fig. 4d \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$ \\alpha $\\end{document} 51 52 53 Fig. 4b \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$ \\alpha $\\end{document} Figure 4 Lymphoid JAK–STAT assembly as an example predicting PI3K \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$ \\alpha $\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$ \\alpha $\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$ \\alpha $\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$ \\alpha $\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$ \\alpha $\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$ \\alpha $\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$ \\alpha $\\end{document} Discussion and conclusion PI3K \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$ \\alpha $\\end{document} 54 \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$ \\alpha $\\end{document} 55 \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$ \\alpha $\\end{document} To achieve this goal, we developed a deep learning model with adaptive domain knowledge, integrating a comprehensive cancer protein systems map. This model aims to elucidate the genetic mechanisms underlying drug resistance and employs transfer learning techniques, specifically CDAN, for high-confidence, quantitative and integrative prediction of PI3K \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$ \\alpha $\\end{document} Fig. S2a Fig. 2 56 57 The biological insights provided by AdaSemb uniquely depend on the composition of the comprehensive cancer protein systems map, presenting both advantages and limitations. One advantage is that the model can integrate information from numerous rare mutations to predict drug responses. These rare alterations, when aggregated, can collectively influence the activity of PA associated with well-characterized cancer-related alterations. A limitation, however, is that the map likely does not encompass all relevant PA (false negatives), and some included assemblies may be incomplete or irrelevant to specific tumor populations (false positives). Nevertheless, the knowledge base of the map positions the precision medicine model as a dynamic entity, capable of being functionally updated with incoming drug response data and structurally updated by integrating additional information. This new data need not be confined to AP-MS experiments (the primary source guiding NeST thus far) [ 58 \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$ \\alpha $\\end{document} Using AdaSemb, we identified seven core assemblies whose genetic variations are associated with PI3K \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$ \\alpha $\\end{document} Fig. S3c \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$ \\alpha $\\end{document} 59 60 61 51 \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$ \\alpha $\\end{document} 52 53 62 63 64 In comparative evaluations, AdaSemb consistently outperformed baseline models across generalization settings, with AdaSemb-PA excelling in cell line tasks and AdaSemb-DRP mitigating degradation in drug and joint scenarios through domain adaptation. This highlights AdaSemb’s robustness in handling structural diversity and distributional shifts, offering reliable predictions where traditional DRP methods falter. This study introduces a predictive model based on an integrative treatment response framework, employing a systematic approach to decipher the resistance mechanisms of PI3K \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$ \\alpha $\\end{document} Materials and methods Pharmacological response profiles were systematically extracted from two major screening platforms: the GDSC and CTRP databases-up to July 2025. The integrated dataset comprised 653461 unique compound-cell line combinations, spanning 1244 distinct cellular models and 912 therapeutic agents, though exhibiting incomplete data coverage for certain entries. The data alignment process for the two datasets was as follows. For drug information, RDKit was used to query each molecule’s published name, synonyms, or SMILES strings. This extracted the corresponding InChIKey. It facilitated the identification of duplicate drugs within and across datasets. For cell viability data, CTRP viability percentage data were standardized using vehicle controls, while GDSC1 and GDSC2 data were normalized based on the “cells only” and “DMSO control” wells on each assay plate, respectively. The data represented the mean values of replicate experiments within each dataset. Drug response was measured using AUDRC, which classifies cell states into three categories: 0 indicates complete cell death, 1 represents an unaffected state, and values greater than 1 suggest that the drug promoted cell growth. When multiple AUDRC values were available for the same drug across different consortia, each replicate was treated as an independent training instance. Among the 888 drugs available in GDSC, 35 drugs (including alpelisib and 34 others) were selected based on significant variability in drug response across different cell lines (corresponding to an SD \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$\\geq $\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$ \\alpha $\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$ \\alpha $\\end{document} Design and training of the AdaSemb model In the DRP task, we embed the NeST gene-assembly hierarchy into a deep neural network. This hierarchy includes 718 genes and 131 PA. The resulting AdaSemb-PA model captures biological factors in cellular drug response. Specifically, we define an input feature matrix X of size \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n${\\text{a}} \\times 3$\\end{document} Supplementary Materials The first layer of AdaSemb-PA transforms these input features into gene-level representations. For each gene \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$ g_{i} $\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n${X_{i}}$\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$ g_{i} $\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$ {\\text{i}} \\in [1,a]$\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$ {X_{i}} \\in{[0,1]^{3}} $\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n${g_{i}} \\in{ \\mathbb{R}}{^{a}}$\\end{document} (1) \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n\\begin{align*}& {g_{i}} = BatchNorm(\\tanh (Linerar({X_{i}})))\\end{align*}\\end{document} BatchNorm refers to batch normalization, tanh indicates the hyperbolic tangent function, and Linear denotes weighted linear transformation. The remaining seven layers of AdaSemb-PA follow the NeST protein assembly hierarchy, where each assembly is represented by several neurons N (as a hyperparameter). A Dropout rate of \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$P$\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$ N \\times 1 $\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$ N \\times N $\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$ {P_{j}} $\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$C$\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$A$\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$ {X_{j}} $\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$ N \\times (N \\cdot C + A) $\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$ {P_{j}} $\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$N$\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n${P_{j}} \\in{\\mathbb{R}^{N}}$\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$ j \\in [1,131] $\\end{document} (2) \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n\\begin{align*}& {P_{j}} = BatchNorm(Tanh(Linear(Dropout({X_{j}}))))\\end{align*}\\end{document} The state of the assembly (referred to as “computational activity”) is defined as a function of the states of its \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$C$\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$A$\\end{document} (3) \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n\\begin{align*}& O = {\\text{Tanh}} (Linear({P_{cell}}))\\end{align*}\\end{document} To further capture the chemical factors influencing cellular drug response within an interpretable model, the AdaSemb-DRP model incorporates a drug embedding branch, implemented using a traditional ANN. This ANN consists of three hidden layers, with neurons in each layer fully connected to the subsequent layer. Specifically, these three layers contain 100, 50 and 6 neurons, respectively. The model input consists of 2048-bit Morgan fingerprints representing drug structures, which are fully connected to the first hidden layer containing 100 neurons. The final layer comprises a set of six neurons, representing the learned drug embeddings in the AdaSemb-DRP model. While deep learning models perform well when handling in-domain data (i.e. from the same distribution), their performance often degrades when applied to cross-domain data with significant distributional shifts. These shifts can notably impact model accuracy, particularly in complex drug response processes, making cross-domain drug sensitivity prediction a challenging task. To address this issue, CDANs have been shown to effectively enhance cross-domain generalization. Thus, we incorporates a CDAN-based transfer learning module into AdaSemb-DRP. This CDAN module consists of three primary components: (i) a genetic feature extractor \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$F( \\cdot )$\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$R( \\cdot )$\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$D( \\cdot )$\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$F( \\cdot )$\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n${f^{C}}$\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n${f^{D}}$\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$R( \\cdot )$\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n${r^{C}}$\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n${r^{D}}$\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$f$\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$r$\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$D( \\cdot )$\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$F( \\cdot )$\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$R( \\cdot )$\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$D( \\cdot )$\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n${L_{s}}$\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n${L_{adv}}$\\end{document} (4) \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n\\begin{align*}& \\mathop{\\min} \\limits_{R} \\mathop{\\max} \\limits_{F,G} {L_{s}}(F,R) - w{L_{adv}}(F,R,D)\\end{align*}\\end{document} Here, \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$\\omega> 0$\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n${L_{adv}}$\\end{document} Model evaluation of PI3K \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$\\boldsymbol\\alpha $\\end{document} We analyzed a PDX dataset containing 212 breast cancer tumor samples [ 52 \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$\\alpha $\\end{document} Fig. S3a Evaluation of key assemblies and genes To assess the potential of specific PA in predicting drug responses in cell lines and PDX models, we applied a variant of the “relative local improvement in predictive power” method previously reported by MA et al 31 \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$j$\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$l \\times N$\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n${Q_{j}}$\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$l$\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$N$\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n${Q_{j}}$\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n${M_{1}},{M_{2}},...,{M_{j}}$\\end{document} (5) \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n\\begin{align*}& {\\min_\\varepsilon} \\parallel{Q_{j}}\\varepsilon - {\\text{I}}\\parallel_{2}^{2} + \\alpha \\parallel \\varepsilon \\parallel_{2}^{2}\\end{align*}\\end{document} Here, \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$\\varepsilon $\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$N$\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$\\alpha $\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$\\rho $\\end{document} To ensure the statistical significance of the assembly importance scores, we generated a null distribution. This was achieved by randomly reshuffling gene membership within each assembly while preserving assembly size and parent–child relationships. Based on this approach, we trained 300 null models and computed the assembly importance for each model. We then applied the Benjamini–Hochberg method to control the false discovery rate (FDR). This allowed us to assess whether the assembly importance scores were significantly higher than those from the null models. Finally, we defined assemblies with an importance score \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$\\geq$\\end{document} \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$\\leq $\\end{document} Statistical analysis The C-index was calculated using the “Lifelines” Python library for survival analysis. All evaluation metrics were computed using the scikit-learn package, while data visualization was performed with matplotlib, seaborn, and ComplexHeatmap. Statistical significance was assessed using two-sided tests conducted in the R environment. Key Points Our work integrates protein assemblies for PI3K \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$ \\alpha $\\end{document} Our work combines genetic variations and drug structures with deep learning. Our method evaluates how tumor genomic profiles modulate PI3K \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$ \\alpha $\\end{document} Our method outperforms traditional biomarkers and predicts survival outcomes. Supplementary Material Supplementary_Materials_bbaf510 Fig4_bbaf510 Fig4_bbaf510 Supplementary_Materials_bbaf510 Supplementary_Table_2_bbaf510 Supplementary_Table_3_bbaf510 Supplementary_Table_4_bbaf510 Supplementary_Table_5_bbaf510 Acknowledgments The authors thank the reviewers for their valuable comments and suggestions. Author contributions Zaiduo Li (Conceptualization, Data curation, Formal analysis, Methodology, Validation, Visualization, Writingoriginal draft, Writingreview & editing), Qiang Yang (Data curation, Writingreview & editing), Long Xu (Conceptualization, Methodology), Weihe Dong (Data curation, Formal analysis), Xiaochuan Yang (Validation), Xianyu Zhang (Conceptualization, Methodology), Tiansong Yang (Conceptualization, Methodology), Xiaokun Li (Conceptualization, Methodology, Writingreview & editing), and Mingliang Liu (Writingreview & editing). Competing interests The authors declare no conflicts of interest. Funding This work was supported by the Natural Science Foundation of Heilongjiang Province of China (No. LH2020F046) and Double First Class Discipline Collaborative Innovation foundation of Heilongjiang province of China (No. LJGXCG2023-54). Data availability The datasets used in this study are all publicly available. GDSC version 1: https://www.cancerrxgene.org/downloads/bulk_download https://www.cancerrxgene.org/downloads/bulk_download https://portals.broadinstitute.org/ctrp.v1/ https://portals.broadinstitute.org/ctrp.v2.1/ https://doi.org/10.6084/m9.figshare.19139906.v1 https://www.nature.com/articles/nm.3954 https://portal.gdc.cancer.gov/projects/TCGA-BRCA https://www.cbioportal.org/datasets https://genie.cbioportal.org/study/summary?id=brca_akt1_genie_2019 https://github.com/li19990317/AdaSemb References 1. Sadybekov AV Katritch V Computational approaches streamlining drug discovery Nature. 2023 616 673 85 10.1038/s41586-023-05905-z 37100941 2. Gupta KK Sharma KK Chandra H et al The integrative bioinformatics approaches to predict the Xanthohumol as anti-breast cancer molecule: targeting cancer cells signaling PI3K and AKT kinase pathway Front Oncol 2022 12 950835 10.3389/fonc.2022.950835 36591523 PMC9798915 3. Yang X Siddique A Khan AA et al Chlamydia trachomatis infection: their potential implication in the etiology of cervical cancer J Cancer 2021 12 4891 900 10.7150/jca.58582 34234859 PMC8247366 4. Khan S Zakariah M Rolfo C et al Prediction of mycoplasma hominis proteins targeting in mitochondria and cytoplasm of host cells and their implication in prostate cancer etiology Oncotarget. 2017 8 30830 43 10.18632/oncotarget.8306 27027344 PMC5458171 5. Khan S Zakariah M Palaniappan S Computational prediction of mycoplasma hominis proteins targeting in nucleus of host cell and their implication in prostate cancer etiology Tumour Biol 2016 37 10805 13 10.1007/s13277-016-4970-9 26874727 6. Khan S Imran A Khan AA et al Systems biology approaches for the prediction of possible role of chlamydia pneumoniae proteins in the etiology of lung cancer PloS One 2016 11 e0148530 10.1371/journal.pone.0148530 26871581 PMC4752481 7. Wang Y Imran A Shami A et al Decipher the Helicobacter pylori protein targeting in the nucleus of host cell and their implications in gallbladder cancer: an in silico approach J Cancer 2021 12 7214 22 10.7150/jca.63517 34729122 PMC8558644 8. Fruman DA Chiu HC Wymann MP The PI3K/AKT signaling pathway in human cancers Oncogene. 2017 36 1436 47 9. Chin L Park PJ Kucherlapati R et al Comprehensive molecular portraits of human breast tumours Nature. 2012 490 61 70 10.1038/nature11412 23000897 PMC3465532 10. Mollon L Aguilar A Anderson E et al A systematic literature review of the prevalence of PIK3CA mutations and mutation hotspots in HR+/HER2-metastatic breast cancer Cancer Res 2018 78 1207 10.1158/1538-7445.AM2018-1207 11. Goncalves MD Hopkins BD Cantley LC Phosphatidylinositol 3-kinase, growth disorders, and cancer N Engl J Med 2018 379 2052 62 10.1056/NEJMra1704560 30462943 12. Miller RM Perry MW PI3K mutations in breast cancer: prognostic and therapeutic implications Breast Cancer: Targets Therapy 2015 7 111 23 10.2147/BCTT.S60696 26028978 PMC4440424 13. Yu M Chen J Xu Z et al Development and safety of PI3K inhibitors in cancer Arch Toxicol 2023 97 635 50 10.1007/s00204-023-03440-4 36773078 PMC9968701 14. Idelalisib MA First global approval Drugs. 2014 74 1701 7 10.1007/s40265-014-0285-6 25187123 15. André F Ciruelos EM Juric D et al Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1 Ann Oncol 2021 32 208 17 10.1016/j.annonc.2020.11.011 33246021 16. André F Ciruelos E Rubovszky G et al Alpelisib for PIK3CA-mutated, hormone receptor–positive advanced breast cancer N Engl J Med 2019 380 1929 40 10.1056/NEJMoa1813904 31091374 17. Vanhaesebroeck B Perry MWD Brown JR et al PI3K inhibitors are finally coming of age Nat Rev Drug Discov 2021 20 741 69 10.1038/s41573-021-00209-1 34127844 PMC9297732 18. Cai Y Xu G Wu F et al Genomic alterations inPIK3CA-mutated breast cancer result in mTORC1 activation and limit the sensitivity to PI3K \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$\\alpha $\\end{document} Cancer Res 2021 81 2470 80 10.1158/0008-5472.CAN-20-3232 33685991 PMC8137641 19. Costa C Wang Y Ly A et al PTEN loss mediates clinical cross-resistance to CDK4/6 and PI3K \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$\\alpha $\\end{document} Cancer Discov 2020 10 72 85 10.1158/2159-8290.CD-18-0830 31594766 20. Brandao M Caparica R Eiger D et al Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors Ann Oncol 2019 30 x27 42 10.1093/annonc/mdz280 31859350 PMC6923785 21. Weiss F Lauffenburger D Friedl P Towards targeting of shared mechanisms of cancer metastasis and therapy resistance Nat Rev Cancer 2022 22 157 73 10.1038/s41568-021-00427-0 35013601 PMC10399972 22. Partin A Brettin TS Zhu Y et al Deep learning methods for drug response prediction in cancer: predominant and emerging trends Front Med 2023 10 1086097 10.3389/fmed.2023.1086097 PMC9975164 36873878 23. Rafique R Islam SMR Kazi JU Machine learning in the prediction of cancer therapy Comput Struct Biotechnol J 2021 19 4003 17 10.1016/j.csbj.2021.07.003 34377366 PMC8321893 24. Tang YC Gottlieb A Explainable drug sensitivity prediction through cancer pathway enrichment Sci Rep 2021 11 3128 10.1038/s41598-021-82612-7 33542382 PMC7862690 25. Jin I Nam H HiDRA: hierarchical network for drug response prediction with attention J Chem Inf Model 2021 61 3858 67 10.1021/acs.jcim.1c00706 34342985 26. Klauschen F Dippel J Keyl P et al Toward explainable artificial intelligence for precision pathology Annu Rev Pathol: Pathol Mech Dis 2024 19 541 70 10.1146/annurev-pathmechdis-051222-113147 37871132 27. Deng L Cai Y Zhang W et al Pathway-guided deep neural network toward interpretable and predictive modeling of drug sensitivity J Chem Inf Model 2020 60 4497 505 10.1021/acs.jcim.0c00331 32804489 28. Zhang H Chen Y Li F Predicting anticancer drug response with deep learning constrained by signaling pathways Front Bioinform 2021 1 639349 10.3389/fbinf.2021.639349 36303766 PMC9581064 29. Kuenzi BM Park J Fong SH et al Predicting drug response and synergy using a deep learning model of human cancer cells Cancer Cell 2020 38 672 684.e6 10.1016/j.ccell.2020.09.014 33096023 PMC7737474 30. Li Y Hostallero DE Emad A Interpretable deep learning architectures for improving drug response prediction performance: myth or reality? Bioinformatics. 2023 39 10.1093/bioinformatics/btad390 PMC10301685 37326960 31. Ma J Yu MK Fong S et al Using deep learning to model the hierarchical structure and function of a cell Nat Methods 2018 15 290 8 10.1038/nmeth.4627 29505029 PMC5882547 32. Elmarakeby HA Hwang J Arafeh R et al Biologically informed deep neural network for prostate cancer discovery Nature. 2021 598 348 52 10.1038/s41586-021-03922-4 34552244 PMC8514339 33. Zhao X Singhal A Park S et al Cancer mutations converge on a collection of protein assemblies to predict resistance to replication stress Cancer Discov 2024 14 508 23 10.1158/2159-8290.CD-23-0641 38236062 PMC10905674 34. Ashburner M Ball CA Blake JA et al Gene ontology: tool for the unification of biology Nat Genet 2000 25 25 9 10.1038/75556 10802651 PMC3037419 35. Gillespie M Jassal B Stephan R et al The reactome pathway knowledgebase 2022 Nucleic Acids Res 2022 50 D687 92 10.1093/nar/gkab1028 34788843 PMC8689983 36. Zheng F Kelly MR Ramms DJ et al Interpretation of cancer mutations using a multiscale map of protein systems Science. 2021 374 eabf3067 10.1126/science.abf3067 34591613 PMC9126298 37. Frampton GM Fichtenholtz A Otto GA et al Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing Nat Biotechnol 2013 31 1023 31 10.1038/nbt.2696 24142049 PMC5710001 38. Beaubier N Tell R Lau D et al Clinical validation of the tempus xT next-generation targeted oncology sequencing assay Oncotarget. 2019 10 2384 96 10.18632/oncotarget.26797 31040929 PMC6481324 39. Smyth LM Zhou Q Nguyen B et al Characteristics and outcome of AKT1E17K-mutant breast cancer defined through AACR project GENIE, a clinicogenomic registry Cancer Discov 2020 10 526 35 10.1158/2159-8290.CD-19-1209 31924700 PMC7125034 40. Rogers D Hahn M Extended-connectivity fingerprints J Chem Inf Model 2010 50 742 54 10.1021/ci100050t 20426451 41. Barretina J Caponigro G Stransky N et al The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity Nature. 2012 483 603 7 10.1038/nature11003 22460905 PMC3320027 42. Seashore-Ludlow B Rees MG Cheah JH et al Harnessing connectivity in a large-scale small-molecule sensitivity dataset Cancer Discov 2015 5 1210 23 10.1158/2159-8290.CD-15-0235 26482930 PMC4631646 43. Basu A Bodycombe NE Cheah JH et al An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules Cell. 2013 154 1151 61 10.1016/j.cell.2013.08.003 23993102 PMC3954635 44. Garnett MJ Edelman EJ Heidorn SJ et al Systematic identification of genomic markers of drug sensitivity in cancer cells Nature. 2012 483 570 5 10.1038/nature11005 22460902 PMC3349233 45. Iorio F Knijnenburg TA Vis DJ et al A landscape of pharmacogenomic interactions in cancer Cell. 2016 166 740 54 10.1016/j.cell.2016.06.017 27397505 PMC4967469 46. Gao H Korn JM Ferretti S et al High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response Nat Med 2015 21 1318 25 10.1038/nm.3954 26479923 47. Migliaccio I Paoli M Risi E et al PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer npj Breast Cancer 2022 8 24 10.1038/s41523-022-00382-5 35181669 PMC8857304 48. Razavi P Dickler MN Shah PD et al Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors Nat Cancer 2020 1 382 93 10.1038/s43018-020-0047-1 32864625 PMC7450824 49. DeGraffenried LA Fulcher L Friedrichs WE et al Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway Ann Oncol 2004 15 1510 6 10.1093/annonc/mdh388 15367412 50. Cutano V Chia ML Wigmore EM et al The interplay between FOXO3 and FOXM1 influences sensitivity to AKT inhibition in PIK3CA and PIK3CA/PTEN altered estrogen receptor positive breast cancer NPJ Breast Cancer 2025 11 36 10.1038/s41523-025-00752-9 40263319 PMC12015352 51. Wang Y Rozen V Zhao Y et al Oncogenic activation of PIK3CA in cancers: emerging targeted therapies in precision oncology Genes Dis 2024 12 101430 10.1016/j.gendis.2024.101430 39717717 PMC11665392 52. Manore SG Doheny DL Wong GL et al IL-6/JAK/STAT3 signaling in breast cancer metastasis: biology and treatment Front Oncol 2022 12 866014 10.3389/fonc.2022.866014 35371975 PMC8964978 53. Wang Y Zhou Q Liu C et al Targeting IL-6/STAT3 signaling abrogates EGFR-TKI resistance through inhibiting Beclin-1 dependent autophagy in HNSCC Cancer Lett 2024 586 216612 10.1016/j.canlet.2024.216612 38211653 54. Juric D Turner N Prat A et al Alpelisib + endocrine therapy in patients with hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer previously treated with CDK4/6 inhibitors: biomarker analyses from the phase II BYLieve study Cancer Res 2022 82 P5-13-03 13 10.1158/1538-7445.SABCS21-P5-13-03 55. Vasan N Razavi P Johnson JL et al DoublePIK3CAmutations in cis increase oncogenicity and sensitivity to PI3K \\documentclass[12pt]{minimal}\n\\usepackage{amsmath}\n\\usepackage{wasysym}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{amsbsy}\n\\usepackage{upgreek}\n\\usepackage{mathrsfs}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n$\\alpha $\\end{document} Science. 2019 366 714 23 10.1126/science.aaw9032 31699932 PMC7173400 56. Hanahan D Weinberg RA Hallmarks of cancer: the next generation Cell. 2011 144 646 74 10.1016/j.cell.2011.02.013 21376230 57. Vogelstein B Kinzler KW Cancer genes and the pathways they control Nat Med 2004 10 789 99 10.1038/nm1087 15286780 58. Richards AL Eckhardt M Krogan NJ Mass spectrometry-based protein–protein interaction networks for the study of human diseases Mol Syst Biol 2021 17 e8792 10.15252/msb.20188792 33434350 PMC7803364 59. Lehmann BD Bauer JA Schafer JM et al PIK3CA mutations in androgen receptor-positive triple-negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors Breast Cancer Res 2014 16 1 14 10.1186/s13058-014-0406-x PMC4187324 25103565 60. Labanca V Bertolini F A combinatorial investigation of the response to anti-angiogenic therapy in breast cancer: new strategies for patient selection and opportunities for reconsidering anti-VEGF, anti-PI3K and checkpoint inhibition EBioMedicine. 2016 10 13 4 10.1016/j.ebiom.2016.07.038 27506898 PMC5006723 61. Wang TH Chen CC Leu YL et al Palbociclib induces DNA damage and inhibits DNA repair to induce cellular senescence and apoptosis in oral squamous cell carcinoma J Formos Med Assoc 2021 120 1695 705 10.1016/j.jfma.2020.12.009 33342707 62. Hu X Li J Fu M et al The JAK/STAT signaling pathway: from bench to clinic Signal Transduct Target Ther 2021 6 402 10.1038/s41392-021-00791-1 34824210 PMC8617206 63. Fathi N Rashidi G Khodadadi A et al STAT3 and apoptosis challenges in cancer Int J Biol Macromol 2018 117 993 1001 10.1016/j.ijbiomac.2018.05.121 29782972 64. De Palma M Biziato D Petrova TV Microenvironmental regulation of tumour angiogenesis Nat Rev Cancer 2017 17 457 74 10.1038/nrc.2017.51 28706266 ",
  "metadata": {
    "Title of this paper": "Microenvironmental regulation of tumour angiogenesis",
    "Journal it was published in:": "Briefings in Bioinformatics",
    "URL": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12477610/"
  }
}